Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MTVA NASDAQ:ONVO NASDAQ:PHIO NASDAQ:TXMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMTVAMetaVia$0.61+0.6%$0.69$0.60▼$4.32$11.93M0.2657,578 shs33,926 shsONVOOrganovo$3.94$1.56▼$21.96$3.47M1.13617,505 shs243,634 shsPHIOPhio Pharmaceuticals$2.33-2.1%$2.36$0.97▼$9.79$11.18M0.862.66 million shs218,759 shsTXMDTherapeuticsMD$1.11-0.9%$1.18$0.70▼$2.44$12.85M0.4224,004 shs9,135 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMTVAMetaVia0.00%-13.63%-6.00%-21.81%+60,899,900.00%ONVOOrganovo0.00%0.00%0.00%0.00%-69.64%PHIOPhio Pharmaceuticals0.00%-14.96%-4.27%+18.88%-27.19%TXMDTherapeuticsMD0.00%-6.72%-0.89%-21.83%-36.57%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMTVAMetaViaN/AN/AN/AN/AN/AN/AN/AN/AONVOOrganovoN/AN/AN/AN/AN/AN/AN/AN/APHIOPhio Pharmaceuticals2.5472 of 5 stars3.53.00.00.01.12.50.6TXMDTherapeuticsMD0.6144 of 5 stars0.05.00.00.00.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMTVAMetaVia 3.00Buy$7.501,131.53% UpsideONVOOrganovo 0.00N/AN/AN/APHIOPhio Pharmaceuticals 3.00Buy$14.00500.86% UpsideTXMDTherapeuticsMD 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ONVO, MTVA, TXMD, and PHIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.006/5/2025PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.005/19/2025MTVAMetaViaMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $3.00(Data available from 8/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMTVAMetaViaN/AN/AN/AN/A$0.92 per shareN/AONVOOrganovo$122K0.00N/AN/A$0.02 per share0.00PHIOPhio PharmaceuticalsN/AN/AN/AN/A$0.69 per shareN/ATXMDTherapeuticsMD$1.76M7.30N/AN/A$2.37 per share0.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMTVAMetaVia-$27.59MN/A0.00N/AN/AN/A-222.13%-123.85%8/13/2025 (Estimated)ONVOOrganovo-$14.67M-$10.20N/AN/AN/A-10,151.64%-346.26%-187.53%N/APHIOPhio Pharmaceuticals-$7.15M-$6.42N/A0.62N/AN/A-105.65%-89.19%8/13/2025 (Estimated)TXMDTherapeuticsMD-$2.18MN/A0.00∞N/A-114.07%-7.86%-5.46%8/11/2025 (Estimated)Latest ONVO, MTVA, TXMD, and PHIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025MTVAMetaVia-$0.32N/AN/AN/AN/AN/A8/13/2025N/APHIOPhio Pharmaceuticals-$0.36N/AN/AN/AN/AN/A5/14/2025Q1 2025MTVAMetaVia-$0.57-$0.36+$0.21-$0.36N/AN/A5/13/2025Q1 2025TXMDTherapeuticsMDN/A-$0.06N/A-$0.06N/A$0.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMTVAMetaViaN/AN/AN/AN/AN/AONVOOrganovoN/AN/AN/AN/AN/APHIOPhio PharmaceuticalsN/AN/AN/AN/AN/ATXMDTherapeuticsMDN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMTVAMetaViaN/A1.551.55ONVOOrganovoN/A0.721.72PHIOPhio PharmaceuticalsN/A10.5810.58TXMDTherapeuticsMDN/A2.642.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMTVAMetaVia1.37%ONVOOrganovo8.23%PHIOPhio Pharmaceuticals57.31%TXMDTherapeuticsMD30.74%Insider OwnershipCompanyInsider OwnershipMTVAMetaVia0.80%ONVOOrganovo3.72%PHIOPhio Pharmaceuticals0.59%TXMDTherapeuticsMD2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMTVAMetaVia819.59 million19.43 millionN/AONVOOrganovo201.70 million14.79 millionOptionablePHIOPhio Pharmaceuticals104.80 million4.77 millionNot OptionableTXMDTherapeuticsMD42011.57 million11.31 millionOptionableONVO, MTVA, TXMD, and PHIO HeadlinesRecent News About These CompaniesTherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors despite daily gainsJuly 16, 2025 | marketwatch.comMarlan D. Walker - TXMD | TherapeuticsMD Inc. - Wall Street JournalJune 29, 2025 | wsj.comMayne Pharma Files Legal Complaint Against TherapeuticsMDJune 1, 2025 | tipranks.comTherapeuticsMD Announces First Quarter 2025 Financial ResultsMay 13, 2025 | businesswire.comTherapeuticsMD Inc. stock rises Monday, still underperforms marketMay 12, 2025 | marketwatch.comTherapeuticsMD Inc. stock outperforms competitors despite losses on the dayApril 8, 2025 | marketwatch.comTherapeuticsMD Announces Full Year 2024 Financial ResultsMarch 27, 2025 | businesswire.comTherapeuticsMD, Inc. (TXMD) Latest Press Releases & Corporate News - Yahoo FinanceMarch 26, 2025 | finance.yahoo.comTherapeuticsMD Inc’s Stock Drama: Could This Be a Game-Changer for TXMD Investors?January 7, 2025 | bovnews.comBTherapeuticsMD Inc (TXMD) Stock: A Deeper Look at Its True PotentialJanuary 3, 2025 | bovnews.comBTherapeuticsMD Inc. stock remains steady Friday, still outperforms marketDecember 27, 2024 | marketwatch.comTherapeuticsMD Inc. stock underperforms Friday when compared to competitors despite daily gainsNovember 23, 2024 | marketwatch.comTherapeuticsMD Shifts Focus with Lower Q3 LossesNovember 14, 2024 | markets.businessinsider.comTherapeuticsMD Reports Reduced Losses Amid Strategic ShiftNovember 14, 2024 | markets.businessinsider.comTherapeuticsMD Announces Third Quarter 2024 Financial ResultsNovember 13, 2024 | finance.yahoo.comTherapeuticsMD Inc. stock remains steady Monday, underperforms marketNovember 12, 2024 | marketwatch.comTherapeuticsMD (NASDAQ:TXMD) Stock, Option ChainNovember 6, 2024 | benzinga.comTherapeuticsMD Inc. stock remains steady Wednesday, underperforms marketNovember 6, 2024 | marketwatch.comTherapeuticsMD Inc. stock underperforms Tuesday when compared to competitors despite daily gainsOctober 22, 2024 | marketwatch.comTherapeuticsMD Inc. stock remains steady Thursday, underperforms marketOctober 17, 2024 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeONVO, MTVA, TXMD, and PHIO Company DescriptionsMetaVia NASDAQ:MTVA$0.61 +0.00 (+0.63%) As of 08/1/2025 03:10 PM EasternMetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.Organovo NASDAQ:ONVOOrganovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.Phio Pharmaceuticals NASDAQ:PHIO$2.33 -0.05 (-2.10%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.32 -0.01 (-0.60%) As of 08/1/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.TherapeuticsMD NASDAQ:TXMD$1.11 -0.01 (-0.89%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.11 0.00 (0.00%) As of 08/1/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
